TF, fibrin, and platelet accumulation in thrombi of wild type mice that received transplants of bone marrow from wild type (WT/WT) or low-TF (LTF/WT) mice. In all experiments, infusion of anti-CD41 was used to detect platelets and antifibrin-specific antibodies were used to detect fibrin. Anti-TF antibodies or irrelevant IgG were infused, as indicated. (A) The thrombus is shown at varying stages of its development as described in Figure 2A. The direction of blood flow is indicated by the white arrow. Top panels are from wild-type bone marrow in a wild-type recipient mouse (WT/WT). Bottom panels show the LTF/WT chimeric mouse. Intravital 4-channel images are as described in Figure 2A. (B) Platelet accumulation. Median values of platelet fluorescence of 32 thrombi from 3 WT/WT mice and 30 thrombi from 4 LTF/WT chimeric mice. (C) Ratio of integrated fluorescence intensity associated with TF to the integrated fluorescence intensity associated with platelets in WT/WT mice. The background fluorescence was determined with a fluorescently labeled nonimmune rabbit IgG. All values shown are median values. WT/WT; 15 thrombi; LTF/WT chimeras, 15 thrombi; and background antibody fluorescence in LTF/WT chimeras, 15 thrombi. Left panel, early phase; right panel, plateau phase. (D) Ratio of integrated fluorescence intensity associated with fibrin to the integrated fluorescence intensity associated with platelets in thrombi formed in WT/WT mice and LTF/WT chimeric mice. Background fluorescence was determined after infusing hirudin (2 U/g body weight) to block fibrin formation. WT/WT, 26 thrombi in 3 mice; LTF/WT chimeric mice, 17 thrombi in 2 mice; and LTF/WT background antibody fluorescence in LTF/WT chimeras, 26 thrombi in 3 mice. Left panel, early phase; right panel, plateau phase. ^*P < .05; ^**P < .025; ^***P < .0025; ^****P < .0005.